Congress moves to legalize cheaper drug imports, threatening pharma pricing power
H.R. 3162 — Affordable and Safe Prescription Drug Importation Act of 2025 · Filed by Jan Schakowsky (D-IL) · 8 cosponsors · Introduced May 1, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill legalizes the importation of FDA-approved prescription drugs from Canada, the UK, EU member states, and Switzerland into the US, allowing wholesale distributors, pharmacies, and individuals to purchase drugs at lower international prices. The FDA must establish a certification system for foreign sellers within one year and can expand permitted countries if safety is demonstrated. Manufacturers are prohibited from charging higher prices to importers or restricting supply to certified foreign sellers, and individuals can import up to a 90-day personal supply with a valid US prescription. The bill aims to reduce drug costs for Americans while maintaining safety oversight through FDA testing, reporting, and enforcement.
Why we flagged it
The bill's core function is to legalize and regulate the importation of FDA-approved prescription drugs from allied nations (Canada, UK, EU, Switzerland) to reduce US drug prices. While framed as consumer protection and cost relief, it directly threatens domestic pharmaceutical pricing power and manufacturer revenue.
What the text implies
- Manufacturers may face pressure to harmonize global pricing, potentially reducing profit margins on US sales—the world's highest-priced pharmaceutical market. This could trigger strategic responses: product reformulation to block importation, supply restrictions to certified foreign sellers, or accelerated price increases before the law takes effect.
- The bill grants HHS broad discretion to expand permitted countries beyond the initial four (Canada, UK, EU, Switzerland) based on safety-equivalence findings. This creates regulatory uncertainty for manufacturers and could eventually include lower-cost producers, further eroding US pricing leverage.
The full analysis lists 5 implications of this text.
Who stands to gain
Consumers and patient advocacy groups (lower out-of-pocket drug costs); Pharmacy chains and mail-order pharmacies (new importation business lines); Foreign pharmacies and wholesalers in Canada, UK, EU, Switzerland (expanded US market access)